Lu vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies [ID3840]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 23 November 2022
Focal therapy using high-intensity focused ultrasound for localised prostate cancerStatus:In developmentProgramme:Interventional procedures guidanceExpected publication date: 5 April 2023
MRI fusion biopsy in people with suspected prostate cancerStatus:In developmentProgramme:Diagnostics guidanceExpected publication date: 17 May 2023
Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer [ID3971]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 24 May 2023
Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Prostate cancer (hormone refractory) - atrasentan [ID390]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Prostate cancer (prevention) - dutasteride [ID75]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Enzalutamide for the treatment of hormone refractory prostate cancer TA316Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Apalutamide with abiraterone acetate and prednisone for treating metastatic hormone-relapsed prostate cancer [ID1480]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)Status:In developmentProgramme:Medical technologies guidanceExpected publication date: TBC
Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer before chemotherapy [ID1619]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer after chemotherapy [ID1621]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Olaparib for previously treated, hormone-relapsed metastatic prostate cancer with homologous recombination repair gene mutations [ID1640]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Niraparib for previously treated hormone-relapsed metastatic prostate cancer with DNA-repair anomalies [ID3782]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer [ID3920 ]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Transperineal biopsy for diagnosing prostate cancerStatus:In developmentProgramme:Diagnostics guidanceExpected publication date: TBC
Irreversible electroporation for treating prostate cancerStatus:In developmentProgramme:Interventional procedures guidanceExpected publication date: TBC